Jasper Therapeutics second quarter 2026 net loss narrows to $2.8M amid Kira acquisition and $132M financing

Jasper Therapeutics reported a net loss of $2.8 million for the second quarter 2026, a significant reduction from the $26.7 million loss in the prior-year period. The quarter’s results were driven by the strategic acquisition of Kira Pharmaceuticals and a subsequent $132 million private placement, which management anticipates will fund operations through the second half of 2028.

Key Highlights

• Secured $132 million in gross proceeds through a private placement of preferred stock, extending the company's cash runway to late 2028.
• Narrowed the quarterly net loss to $2.8 million, aided by a $4.0 million non-cash gain from the change in fair value of warrant liabilities.
• Anticipates interim Stage 1 data for lead asset KP-104 in rare renal indications during the fourth quarter of 2026.